Cited by 130Hormonal Regulation and HypertensionEstrogen and related hormone effectsAdrenal Hormones and Disorders

Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor

Quinkler, M, Meyer, B, Bumke-Vogt, C, Grossmann, C, Gruber, U, Oelkers, W, Diederich, S, Bahr, V·2002·European Journal of Endocrinology

Abstract

OBJECTIVE: Progesterone binds to the human mineralocorticoid receptor (hMR) with nearly the same affinity as do aldosterone and cortisol, but confers only low agonistic activity. It is still unclear how aldosterone can act as a mineralocorticoid in situations with high progesterone concentrations, e.g. pregnancy. One mechanism could be conversion of progesterone to inactive compounds in hMR target tissues. DESIGN: We analyzed the agonist and antagonist activities of 16 progesterone metabolites by their binding characteristics for hMR as well as functional studies assessing transactivation. METHODS: We studied binding affinity using hMR expressed in a T7-coupled rabbit reticulocyte lysate system. We used co-transfection of an hMR expression vector together with a luciferase reporter gene in CV-1 cells to investigate agonistic and antagonistic properties. RESULTS: Progesterone and 11beta-OH-progesterone (11beta-OH-P) showed a slightly higher binding affinity than cortisol, deoxycorticosterone and aldosterone. 20alpha-dihydro(DH)-P, 5alpha-DH-P and 17alpha-OH-P had a 3- to 10-fold lower binding potency. All other progesterone metabolites showed a weak affinity for hMR. 20alpha-DH-P exhibited the strongest agonistic potency among the metabolites tested, reaching 11.5% of aldosterone transactivation. The agonistic activity of 11beta-OH-P, 11alpha-OH-P and 17alpha-OH-P was 9, 5.1 and 4.1% respectively. At a concentration of 100 nmol/l, progesterone, 17alpha-OH-P and 20alpha-DH-P inhibit nearly 75, 40 and 35% of the transactivation by aldosterone respectively. All other progesterone metabolites tested demonstrate weaker affinity, and agonistic and antagonistic potency. CONCLUSIONS: The binding affinity for hMR and the agonistic and antagonistic activity diminish with increasing reduction of the progesterone molecule at C20, C17 and at ring A. We assume that progesterone metabolism to these compounds is a possible protective mechanism for hMR. 17alpha-OH-P is a strong hMR antagonist and could exacerbate mineralocorticoid deficiency in patients with congenital adrenal hyperplasia.

Integrity signals

Registry

Crossref · 10.1530/eje.0.1460789

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The transactivation activities of progesterone and 17OHP were only 0.2 to 0.8% of that for cortisol, whereas the transactivation activity of 21-deoxycortisol was 8.5% and 17% in two different assays.

    “However, the transactivation activities of progesterone and 17OHP were only 0.2 to 0.8% of that for cortisol, whereas the transactivation activity of 21-deoxycortisol was 8.5% and 17% in two different assays (137,138).”
  • In vitro, 21-deoxycortisol, corticosterone, 17OHP, and progesterone bind the glucocorticoid receptor with 24-43% of the affinity of cortisol.

    “In vitro, 21-deoxycortisol, corticosterone, 17OHP, and progesterone bind the glucocorticoid receptor with 24-43% of the affinity of cortisol.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Quinkler, M., Meyer, B., Bumke-Vogt, C., Grossmann, C., Gruber, U., Oelkers, W., Diederich, S., & Bahr, V
Affiliations
Freie Universität Berlin (DE)
Corresponding author
Quinkler, M
Venue
European Journal of Endocrinology
Published
2002-06-01
Volume
146
Issue
6
Pages
789-799
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2165755939
Cited by
130
References
59
Citations by year
2026: 4 · 2025: 3 · 2024: 8 · 2023: 8 · 2022: 6 · 2021: 7 · 2020: 8 · 2019: 7 · 2018: 3 · 2017: 7 · 2016: 8 · 2015: 5 · 2014: 10 · 2013: 3 · 2012: 3
FWCI
1.73
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Deutsche Forschungsgemeinschaft
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
progesterone metabolites, receptor binding affinity, agonist activity, antagonist activity, 17-hydroxyprogesterone, 20alpha-dihydroprogesterone, 11β-hydroxyprogesterone, aldosterone, mineralocorticoid deficiency, congenital adrenal hyperplasia, pregnancy, transcriptional activation
MeSH terms
Aldosterone, Mineralocorticoid Receptor Antagonists, Animals, Desoxycorticosterone, Humans, Hydrocortisone, Luciferases, Progesterone, Rabbits, Reticulocytes, Transcription, Genetic, Transfection, Protein Biosynthesis, Transcriptional Activation, Receptors, Mineralocorticoid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review